No Data
No Data
Yifan Pharmaceutical (002019.SZ): The company has not produced products for this indication (monkeypox).
Yifan Pharmaceutical (002019.SZ) stated on the investor interaction platform on August 31st that the company does not produce products for this indication (monkeypox); at the same time, kindly remind investors not to believe rumors, to rationally distinguish various types of information, and to pay attention to investment risks.
Yifan Pharmaceutical Co., Ltd. (SZSE:002019) Might Not Be As Mispriced As It Looks
Yifan Pharmaceutical: Half-year report for the year 2024.
Yifan Pharmaceutical: Summary of Half-Year Report in 2024.
Yifan Pharmaceutical's Unit Gets Regulatory Nod for Muscle Pain Reliever
Yifan Pharmaceutical (002019.SZ): obtained the pharmaceutical registration certificate for Mesoba Mo injection.
On August 6th, Gelonhui reported that Yifan Pharmaceutical (002019.SZ) announced that its wholly-owned subsidiary, Hefei Yifan Biopharmaceutical Co., Ltd., received the Approval of Registration Certificate for Mosapramine Injection from the National Medical Products Administration on August 5, 2024. Mosapramine Injection is mainly used to treat acute skeletal muscle pain or discomfort. According to IQVIA data, the global sales of Mosapramine Injection in 2023 were 40.43 million US dollars. According to Minet data, the domestic sales of Mosapramine Injection in 2023 were 330 million yuan. As of the date of the report disclosure, the company had not yet achieved sales of Mesobom.
No Data